Compare Vanguard Mega Cap Growth ETF (MGK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Tango Therapeutics Inc. — how do they compare? Vanguard Mega Cap Growth ETF trades at $91.14 (market cap $33.70B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 9× Tango Therapeutics Inc.'s market cap, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and Tango Therapeutics Inc. for 0 Days on average.
| MGK | TNGX | |
|---|---|---|
Market Cap | $33.70B | $3.75B |
Volume | 775,002 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $32.90 |
52-Week Low | $70.70 | $7.50 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $94.19, up 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking large-cap U.S. growth stocks like Nvidia and Apple, lacks disclosed fundamental ratios but benefits from a low 0.05% expense ratio and recent positive media coverage highlighting its long-term growth potential and tech concentration.
The outlook for MGK is favorable for growth-oriented investors, driven by its focus on mega-cap tech leaders, though concentration risk and market volatility pose challenges. Analyst sentiment is broadly positive, with the ETF positioned to capitalize on sustained growth trends, but investors should weigh its reliance on top holdings against diversification needs.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
